Siemens Healthineers AG

Siemens AG’s partial divestiture of Siemens Healthineers unlocks AI‑driven imaging growth and value‑based care, boosting agility, margins and patient access.

Siemens Healthineers partners with Cohen Veterans Bioscience to expand the National Normative Neuroimaging Library, adding blood‑based biomarkers for earlier, precise brain disorder diagnosis and improved patient care.

Siemens Healthineers reports a 3.4 % revenue dip driven by US tariff hikes, yet keeps dividends steady; investors await next‑quarter earnings and a cautious 2025 profit outlook.

Siemens Healthineers, a global medical technology leader, faces market pressure and valuation challenges due to concerns over a potential sell-down of its parent company, Siemens AG, and the impact of reimbursement reform, regulatory pressure, and r…

Siemens Healthineers AG is navigating market volatility while advancing its clinical impact, driven by robust financial performance, solid regulatory track record, and commitment to patient-centric innovation.

Siemens Healthineers AG navigates a complex landscape of growth opportunities and challenges in the medical technology sector, driven by factors such as regulatory changes, competition, and emerging trends in tele-diagnostics and sustainability.

Siemens Healthineers AG navigates market dynamics and reimbursement landscapes, with analysts maintaining a ‘buy’ consensus despite the company’s share price trading near its 52-week low, driven by a diversified revenue model and strong financial fo…

Siemens Healthineers AG, a leading medical technology company, is navigating uncertainty due to potential US tariffs on medical products, which has led to a decline in its share price and raised concerns about its revenue and margins.

Siemens Healthineers AG continues to solidify its position as a leader in medical technology through strategic partnerships, talent acquisitions, and a focus on core product categories, despite a volatile macroeconomic environment.

Siemens Healthineers is considering selling its diagnostics division, a move that could either revitalize the company’s strategic focus or deepen its stock’s volatility, as investors weigh the potential benefits and drawbacks of the sale.